GenSight Biologics reports critical liquidity and €16 million funding need
GenSight Biologics reported critically low liquidity and an urgent need for €16 million in additional funding to continue operations and support the planned RECOVER Phase III trial. The same summary cited negative reported revenue after an accounting-estimate change and a €10.3 million net loss. A company financial-results disclosure separately said its available resources were insufficient for the next 12 months and warned that failure to secure funding could delay operating plans or ultimately lead to insolvency or cessation of operations.
GenSight Biologics faces an explicit liquidity shortfall that could affect continued operations and the planned RECOVER Phase III trial, making financial_distress more appropriate than business_performance or financing; no financing has actually been completed. The trading summary reports negative reported revenue, a €10.3 million net loss and an urgent €16 million funding need, while the company-results disclosure independently supports insufficient resources and the need for additional funding. Because the exact figures are not corroborated across all retrieved context, confidence is below the high-confidence range. The timestamp uses the September 29 disclosure date rather than the wire publication time because the actual event time was not provided.
Early access programs for GS010/LUMEVOQ® generated first commercial revenues, but a change in accounting estimate led to negative reported revenue and a wider net loss of €10.3 million. Liquidity remains critically low, with urgent need for €16 million in additional funding to support ongoing operations and the planned RECOVER Phase III trial.